CWM
BMRN icon

Calamos Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Calamos Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-4,592
Closed -$349K – 281
2020
Q3 		$349K Sell
4,592
-76
-2% -$7.69K 0.04% 217
2020
Q2 		$576K Buy
+4,668
New +$464K 0.07% 164
2017
Q1 		– Sell
-14,625
Closed -$1.21M – 235
2016
Q4 		$1.21M Sell
14,625
-1,141
-7% -$98.1K 0.2% 139
2016
Q3 		$1.46M Buy
+15,766
New +$1.48M 0.25% 127

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Calamos Wealth Management's BMRN Position: Q4 2020 in Review

Calamos Wealth Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2020, closing a stake of 4,592 shares — an estimated $349K sold.

Calamos Wealth Management first reported a position in BMRN in Q3 2016 and held it in 4 quarters. The position peaked at $1.46M in Q3 2016. 539 funds tracked by Wall St. Rank hold BMRN as of Q4 2020.

  • Calamos Wealth Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Calamos Wealth Management sold 4,592 BioMarin Pharmaceuticals shares in Q4 2020, an estimated $349K.
  • Calamos Wealth Management first reported a position in BioMarin Pharmaceuticals in Q3 2016 and held it in 4 quarters.
  • Calamos Wealth Management's BioMarin Pharmaceuticals position peaked at $1.46M in Q3 2016.
  • 539 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2020.

Based on Calamos Wealth Management's 13F filing for Q4 2020, filed 27 Jan 2021.